As a first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, the PD-L1 inhibitor durvalumab plus weekly carboplatin and paclitaxel provided clinically significant efficacy in the phase II FRAIL-IMMUNE (GORTEC 2018-03) trial. 1 This regimen may prove to be an effective first-line option, especially for patients who cannot tolerate cisplatin, said Jérome Fayette, MD, PhD, of Centre Léon Bérard, Lyon, France, who reported the findings at the 2023 ASCO Annual Meeting. 1 “This

In a phase I study from Memorial Sloan Kettering Cancer Center (MSK), New York, the combination of cabozantinib and cetuximab showed antitumor efficacy in heavily pretreated patients with recurrent or metastatic head and neck squamous cell cancer. 1 Antoine Desilets, MD, an advanced oncology fellow at MSK who presented the findings in a poster at the 2023 ASCO Annual Meeting, 1 explained the rationale for this combination. “EGFR targeting with cetuximab is a standard therapy for head and neck squamous

Investigators reported that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those patients with a normal or obese BMI, according to a recent study published by Sung Jun Ma, MD, a resident physician in the Department of Radiation Medicine at Roswell Park Comprehensive Cancer Center, Buffalo, New York, and colleagues, in JAMA Network Open. 1 The new

By The ASCO Post Staff Posted: 7/7/2023 10:47:00 AM Last Updated: 7/7/2023 12:44:58 PM Investigators have found that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional…